These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35565243)

  • 21. Comparative Efficacy of Drugs for the Treatment of Chronic Constipation: Quantitative Information for Medication Guidelines.
    Zhang Y; Yin F; Xu L; Li YF; Chen JC; Liu HX; Zheng QS; Li LJ
    J Clin Gastroenterol; 2020; 54(10):e93-e102. PubMed ID: 31904680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
    Jansen JP; Lorch D; Langan J; Lasko B; Hermanns K; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
    J Pain; 2011 Feb; 12(2):185-93. PubMed ID: 21292169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
    Webster L; Dhar S; Eldon M; Masuoka L; Lappalainen J; Sostek M
    Pain; 2013 Sep; 154(9):1542-1550. PubMed ID: 23726675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Evidence for the Safety and Effectiveness of Naldemedine in the Management of Opioid-Induced Constipation in Patients With Cancer Pain: Post-hoc Subgroup Analysis of Post-marketing Surveillance in Japan.
    Naya N; Oka H; Hashimoto S; Morioka Y; Kizawa Y
    Cureus; 2023 Sep; 15(9):e46090. PubMed ID: 37900431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients.
    Christie J; Shroff S; Shahnavaz N; Carter LA; Harrison MS; Dietz-Lindo KA; Hanfelt J; Srinivasan S
    Am J Gastroenterol; 2017 Feb; 112(2):356-364. PubMed ID: 27922028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects.
    Sanders M; Jones S; Löwenstein O; Jansen JP; Miles H; Simpson K
    Pain Med; 2015 Aug; 16(8):1540-50. PubMed ID: 26110375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes.
    Spierings ELH; Drossman DA; Cryer B; Mazen Jamal M; Losch-Beridon T; Mareya SM; Wang M
    Pain Med; 2018 Jun; 19(6):1184-1194. PubMed ID: 29016868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
    Irving G; Pénzes J; Ramjattan B; Cousins M; Rauck R; Spierings EL; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
    J Pain; 2011 Feb; 12(2):175-84. PubMed ID: 21292168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploratory, multicenter, open-label study to evaluate the effects of linaclotide in patients with chronic constipation with an insufficient response to magnesium oxide: A study protocol.
    Yoshihara T; Kessoku T; Takatsu T; Misawa N; Ashikari K; Fuyuki A; Ohkubo H; Higurashi T; Iwaki M; Kurihashi T; Nakatogawa M; Yamamoto K; Terada I; Tanaka Y; Nakajima A
    Contemp Clin Trials Commun; 2022 Dec; 30():101019. PubMed ID: 36387985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Schoenfeld P; Lacy BE; Chey WD; Lembo AJ; Kurtz CB; Reasner DS; Bochenek W; Tripp K; Currie MG; Fox SM; Blakesley RE; OʼDea CR; Omniewski ND; Hall ML
    Am J Gastroenterol; 2018 Jan; 113(1):105-114. PubMed ID: 29091082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies.
    Osaka I; Ishiki H; Yokota T; Tada Y; Sato H; Okamoto M; Satomi E
    ESMO Open; 2019; 4(4):e000527. PubMed ID: 31423335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Elobixibat in Patients with Diabetes and Concomitant Chronic Constipation: an 8-week, Prospective, Single-center, Single-arm Study.
    Hishida Y; Nagai Y; Tsukiyama H; Nakamura Y; Nakagawa T; Ishizaki S; Tanaka Y; Sone M
    Adv Ther; 2022 Sep; 39(9):4205-4217. PubMed ID: 35867276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.
    Cryer B; Katz S; Vallejo R; Popescu A; Ueno R
    Pain Med; 2014 Nov; 15(11):1825-34. PubMed ID: 24716835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Establishing Minimal Clinically Important Differences in Quality of Life Measures in Opioid-Induced Constipation.
    Tack J; Camilleri M; Hale M; Morlion B; Nalamachu S; Webster L; Wild J
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):855-863. PubMed ID: 33965574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation.
    DeMicco M; Barrow L; Hickey B; Shailubhai K; Griffin P
    Therap Adv Gastroenterol; 2017 Nov; 10(11):837-851. PubMed ID: 29147135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation.
    Mueller-Lissner S; Kamm MA; Wald A; Hinkel U; Koehler U; Richter E; Bubeck J
    Am J Gastroenterol; 2010 Apr; 105(4):897-903. PubMed ID: 20179697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class.
    Webster LR; Brewer RP; Lichtlen P; Losch-Beridon T; Mareya S; Wang M
    Pain Med; 2018 Jun; 19(6):1195-1205. PubMed ID: 29897589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.
    Jamal MM; Adams AB; Jansen JP; Webster LR
    Am J Gastroenterol; 2015 May; 110(5):725-32. PubMed ID: 25916220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Acupoint embedding for female functional constipation:a randomized controlled trial].
    Chen L; Jin X; Jiang X; Wang C; Shi Y; Wang L
    Zhongguo Zhen Jiu; 2017 Jul; 37(7):717-721. PubMed ID: 29231544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Naldemedine for Opioid-Induced Constipation in Children.
    Miura R; Utano T; Miura Y; Chiba K; Hasegawa A; Takafuji Y; Takahashi H; Tanzawa A; Iwahashi K; Yamatani A; Yotani N
    J Palliat Med; 2024 Aug; ():. PubMed ID: 39122251
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.